These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36056913)

  • 21. Novel evidence of Thymosin α1 immunomodulatory properties in SARS-CoV-2 infection: Effect on innate inflammatory response in a peripheral blood mononuclear cell-based in vitro model.
    Ricci D; Etna MP; Severa M; Fiore S; Rizzo F; Iannetta M; Andreoni M; Balducci S; Stefanelli P; Palamara AT; Coccia EM
    Int Immunopharmacol; 2023 Apr; 117():109996. PubMed ID: 36933449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Thymosin alpha 1 for the adjuvant treatment of coronavirus disease 2019: a retrospective cohort study].
    Wang T; Lin Q; Xie Y; Yang L; Cao S; Dong H; Du J; Wang R
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 May; 34(5):497-501. PubMed ID: 35728851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thymosin alpha 1 treatment for patients with sepsis.
    Pei F; Guan X; Wu J
    Expert Opin Biol Ther; 2018 Jul; 18(sup1):71-76. PubMed ID: 30063866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thymosin α1 and Its Role in Viral Infectious Diseases: The Mechanism and Clinical Application.
    Tao N; Xu X; Ying Y; Hu S; Sun Q; Lv G; Gao J
    Molecules; 2023 Apr; 28(8):. PubMed ID: 37110771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thymosin α1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients.
    Jia Z; Feng Z; Tian R; Wang Q; Wang L
    Immunopharmacol Immunotoxicol; 2015; 37(4):388-92. PubMed ID: 26250523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results.
    Moscarella S; Buzzelli G; Romanelli RG; Monti M; Giannini C; Careccia G; Marrocchi EM; Zignego AL
    Liver; 1998 Oct; 18(5):366-9. PubMed ID: 9831367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy of thymosin alpha-1 therapy in moderate to critical COVID-19 patients: a systematic review, meta-analysis, and meta-regression.
    Soeroto AY; Suryadinata H; Yanto TA; Hariyanto TI
    Inflammopharmacology; 2023 Dec; 31(6):3317-3325. PubMed ID: 37845598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of thymosin α1 on mortality of critical COVID-19 patients: A multicenter retrospective study.
    Sun Q; Xie J; Zheng R; Li X; Chen H; Tong Z; Du B; Qiu H; Yang Y
    Int Immunopharmacol; 2021 Jan; 90():107143. PubMed ID: 33208294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials.
    Liu F; Wang HM; Wang T; Zhang YM; Zhu X
    BMC Infect Dis; 2016 Sep; 16():488. PubMed ID: 27633969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COVID-19 and beyond: Reassessing the role of thymosin alpha1 in lung infections.
    Bellet MM; Renga G; Pariano M; Stincardini C; D'Onofrio F; Goldstein AL; Garaci E; Romani L; Costantini C
    Int Immunopharmacol; 2023 Apr; 117():109949. PubMed ID: 36881979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy.
    Danielli R; Cisternino F; Giannarelli D; Calabrò L; Camerini R; Savelli V; Bova G; Dragonetti R; Di Giacomo AM; Altomonte M; Maio M
    Expert Opin Biol Ther; 2018 Jul; 18(sup1):77-83. PubMed ID: 30063847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study.
    Mutchnick MG; Lindsay KL; Schiff ER; Cummings GD; Appelman HD; Peleman RR; Silva M; Roach KC; Simmons F; Milstein S; Gordon SC; Ehrinpreis MN
    J Viral Hepat; 1999 Sep; 6(5):397-403. PubMed ID: 10607256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of Tα1 on the infective patients after hematopoietic stem cell transplantation.
    Ding JH; Wang LL; Chen Z; Wang J; Yu ZP; Zhao G; Chen BA
    Int J Hematol; 2013 Feb; 97(2):280-3. PubMed ID: 23307511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improvement in cognitive dysfunction following blast induced traumatic brain injury by thymosin α1 in rats: Involvement of inhibition of tau phosphorylation at the Thr205 epitope.
    Shi QX; Chen B; Nie C; Zhao ZP; Zhang JH; Si SY; Cui SJ; Gu JW
    Brain Res; 2020 Nov; 1747():147038. PubMed ID: 32738231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thymosin alpha 1: biological activities, applications and genetic engineering production.
    Li J; Liu CH; Wang FS
    Peptides; 2010 Nov; 31(11):2151-8. PubMed ID: 20699109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study.
    Wang X; Li W; Niu C; Pan L; Li N; Li J
    Inflammation; 2011 Jun; 34(3):198-202. PubMed ID: 20549321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulatory role of thymosin-alpha-1 in normal bone-marrow haematopoiesis and its effect on myelosuppression in T-cell lymphoma bearing mice.
    Paul S; Sodhi A
    Immunol Lett; 2002 Jul; 82(3):171-82. PubMed ID: 12036599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Double-blind Multicenter Two-arm Randomized Placebo-controlled Phase-III Clinical Study to Evaluate the Effectiveness and Safety of Thymosin α1 as an Add-on Treatment to Existing Standard of Care Treatment in Moderate-to-severe COVID-19 Patients.
    Shetty A; Chandrakant NS; Darnule RA; Manjunath BG; Sathe P
    Indian J Crit Care Med; 2022 Aug; 26(8):913-919. PubMed ID: 36042753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of Gemcitabine and Thymosin alpha 1 exhibit a better anti-tumor effect on nasal natural killer/T-cell lymphoma.
    Chen M; Jiang Y; Cai X; Lu X; Chao H
    Int Immunopharmacol; 2021 Sep; 98():107829. PubMed ID: 34119916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.